AptarGroup (ATR)
NYSE:ATR
Want to see ATR full AI Analyst Report?
ATR Stock Chart & Stats
$130.63
-$0.05(-0.03%)
At close: 4:00 PM EST
$130.63
-$0.05(-0.03%)
Day’s Range― - ―
52-Week Range$103.23 - $164.28
Previous CloseN/A
Volume34.64K
Average Volume (3M)483.20K
Market Cap
$7.84B
Enterprise Value$9.04B
Total Cash (Recent Filing)$409.53M
Total Debt (Recent Filing)$1.53B
Price to Earnings (P/E)20.4
Beta0.57
Next Earnings
Apr 30, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,772,670
10 Day Avg. Volume422,865
30 Day Avg. Volume483,202
Financial Highlights & Ratios
PEG Ratio3.60
Price to Book (P/B)3.01
Price to Sales (P/S)2.12
P/FCF Ratio26.76
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.39
Enterprise Value/Gross Profit8.09
Enterprise Value/Ebitda10.87
Forecast
1Y Price Target
$153.00Price Target Upside17.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)5.57
Revenue Forecast (FY)$3.94B
Bulls Say, Bears Say
Bulls Say
China ProfitabilityAptar's China operations are expected to be more profitable than the company average, offering a route to lift overall margins as the regional footprint strengthens.
Injectables DemandExpansion of GLP-1 therapies and continued demand for biologics should increase demand for the Injectables business, with oral dosing not viewed as a direct substitute due to delivery requirements.
Management ExecutionManagement expressed confidence in execution across the Pharma, Beauty, and Closures businesses, which supports expectations for sustained broad-based revenue growth and more consistent operational performance.
Bears Say
Emergency Medicine DemandDeclining demand for emergency medicines, including Narcan, creates a sizeable revenue headwind that will pressure overall sales and earnings.
Margins And ProfitabilityDeterioration in margins driven by loss of high-margin product revenue and a shift toward increased lower-margin tooling sales has weakened profitability and could limit future earnings expansion.
Operational DisruptionsUnusual maintenance problems and a supplier fire disrupted operations, interrupting production and adding uncertainty to results.
AptarGroup News
ATR FAQ
What was AptarGroup’s price range in the past 12 months?
AptarGroup lowest stock price was $103.23 and its highest was $164.28 in the past 12 months.
What is AptarGroup’s market cap?
AptarGroup’s market cap is $7.84B.
When is AptarGroup’s upcoming earnings report date?
AptarGroup’s upcoming earnings report date is Apr 30, 2026 which is today.
How were AptarGroup’s earnings last quarter?
Currently, no data Available
Is AptarGroup overvalued?
According to Wall Street analysts AptarGroup’s price is currently Undervalued.
Does AptarGroup pay dividends?
AptarGroup pays a Quarterly dividend of $0.48 which represents an annual dividend yield of 1.5%. See more information on AptarGroup dividends here
What is AptarGroup’s EPS estimate?
AptarGroup’s EPS estimate is 1.15.
How many shares outstanding does AptarGroup have?
AptarGroup has 63,772,670 shares outstanding.
What happened to AptarGroup’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AptarGroup?
Currently, no hedge funds are holding shares in ATR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AptarGroup Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$153.00 (17.12% Upside)
$153.00 (17.12% Upside)
Blogger Sentiment
Bullish
ATR Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 23.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $770.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.95%
12-Months-Change
Fundamentals
Return on Equity
14.68%
Trailing 12-Months
Asset Growth
18.51%
Trailing 12-Months
Company Description
AptarGroup
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
ATR Company Deck
ATR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of clear operational and commercial strengths—notably strong Q4 revenue growth, sustained Pharma pipeline momentum (including FDA approval of CARDAMYST), meaningful tooling and commercial wins in Beauty and Closures, solid capital returns and a healthy balance sheet—while also disclosing significant near-term margin pressures driven by emergency medicine destocking (~$65 million headwind), operational disruptions in Beauty and Closures, higher interest and tax expenses, and a sizable Q4 EPS decline. Management emphasized that many negative items are transitory, expects sequential margin improvement through 2026 and reaffirmed productivity programs and buyback flexibility. Overall, positive revenue and pipeline momentum are meaningfully offset by near-term margin and cost challenges, leaving a balanced outlook.View all ATR earnings summariesATR Stock 12 Month Forecast
Average Price Target
$153.00
▲(17.12% Upside)
Technical Analysis
Baxter International
―
Cooper Co
―
Repligen
―
West Pharmaceutical Services
―
Stevanato Group
―
Ownership Overview
0.72% Insiders
31.22% Mutual Funds
4.14% Other Institutional Investors
38.24% Public Companies and
Individual Investors